WO2008046087A3 - Spiro compounds and their uses as therapeutic agents - Google Patents

Spiro compounds and their uses as therapeutic agents Download PDF

Info

Publication number
WO2008046087A3
WO2008046087A3 PCT/US2007/081323 US2007081323W WO2008046087A3 WO 2008046087 A3 WO2008046087 A3 WO 2008046087A3 US 2007081323 W US2007081323 W US 2007081323W WO 2008046087 A3 WO2008046087 A3 WO 2008046087A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agents
compounds
spiro compounds
spiro
tautomer
Prior art date
Application number
PCT/US2007/081323
Other languages
French (fr)
Other versions
WO2008046087A2 (en
Inventor
Sultan Chowdhury
Jianmin Fu
Rajender Kamboj
Shifeng Liu
Qi Jia
Vandna Raina
Jianyu Sun
Original Assignee
Xenon Pharmaceuticals Inc
Sultan Chowdhury
Jianmin Fu
Rajender Kamboj
Shifeng Liu
Qi Jia
Vandna Raina
Jianyu Sun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc, Sultan Chowdhury, Jianmin Fu, Rajender Kamboj, Shifeng Liu, Qi Jia, Vandna Raina, Jianyu Sun filed Critical Xenon Pharmaceuticals Inc
Publication of WO2008046087A2 publication Critical patent/WO2008046087A2/en
Publication of WO2008046087A3 publication Critical patent/WO2008046087A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is directed to spiro-benzoisothiazole derivatives of formula (I), wherein j, k, m, q, Z, Q, R1, R2 and R3 are each as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.
PCT/US2007/081323 2006-10-12 2007-10-12 Spiro compounds and their uses as therapeutic agents WO2008046087A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85109606P 2006-10-12 2006-10-12
US60/851,096 2006-10-12

Publications (2)

Publication Number Publication Date
WO2008046087A2 WO2008046087A2 (en) 2008-04-17
WO2008046087A3 true WO2008046087A3 (en) 2008-11-27

Family

ID=39204860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081323 WO2008046087A2 (en) 2006-10-12 2007-10-12 Spiro compounds and their uses as therapeutic agents

Country Status (1)

Country Link
WO (1) WO2008046087A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105147760A (en) * 2015-09-28 2015-12-16 成都倍加特生物科技有限公司 Externally-used soak liquor capable of treating erythromelalgia and preparation method

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (en) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc SPIROHETEROCICLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
WO2008060789A2 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AU2009303468B2 (en) 2008-10-17 2014-08-28 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010053998A1 (en) * 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Spiro-condensed indole derivatives as sodium channel inhibitors
US20110269788A1 (en) * 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
AR077252A1 (en) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc ESPIROOXINDOL COMPOUND ENANTIOMERS AND THEIR USES AS THERAPEUTIC AGENTS
ES2467166T3 (en) 2009-10-14 2014-06-12 Xenon Pharmaceuticals Inc. Methods of synthesis of spiro-oxindole compounds
BR112012021086A2 (en) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2012049555A1 (en) 2010-10-13 2012-04-19 Lupin Limited Spirocyclic compounds as voltage-gated sodium channel modulators
CA2869547A1 (en) 2012-04-12 2013-10-17 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
EP3126360A1 (en) 2014-03-29 2017-02-08 Lupin Limited Sulfonamide compounds as voltage gated sodium channel modulators
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
TW201722938A (en) 2015-09-04 2017-07-01 魯賓有限公司 Sulfonamide compounds as voltage-gated sodium channel modulators
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
WO2018163077A1 (en) 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators
CN109761993B (en) * 2019-01-31 2021-03-23 广西师范大学 Spirobenzofuran-3, 3' -quinoline derivative and synthesis method and application thereof
CN111100058B (en) * 2019-11-22 2023-02-07 华东师范大学 3, 3-dicarboxylic acid ester-indoline-2-thioketone compound and synthetic method and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422217A2 (en) * 1998-04-01 2004-05-26 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US20040167224A1 (en) * 2002-03-14 2004-08-26 Fumihiro Ozaki Nitrogen containing heterocyclic compounds and medicines containing the same
WO2005035498A1 (en) * 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. Use of nitrogenous bicyclic compound as feeding control agent
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
WO2006110654A1 (en) * 2005-04-11 2006-10-19 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
WO2006110917A2 (en) * 2005-04-11 2006-10-19 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422217A2 (en) * 1998-04-01 2004-05-26 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US20040167224A1 (en) * 2002-03-14 2004-08-26 Fumihiro Ozaki Nitrogen containing heterocyclic compounds and medicines containing the same
WO2005035498A1 (en) * 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. Use of nitrogenous bicyclic compound as feeding control agent
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
WO2006110654A1 (en) * 2005-04-11 2006-10-19 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
WO2006110917A2 (en) * 2005-04-11 2006-10-19 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their uses as therapeutic agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHAU-CHEN YANG ET AL.: "Nucleophilic-type radical cyclisations of indoles: conversion of 2-cyano 3-substituted indoles to spiro-annelated indolines and tetrahydrocarbazoles", J. ORG. CHEM., vol. 58, 1993, pages 3100 - 3105, XP002498177 *
FRASER SCOTT P ET AL: "Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5381 - 5389, XP002415107, ISSN: 1078-0432 *
NICOLAUS B J R: "Symbiotic Approach to Drug Design", DECISION MAKING IN DRUG RESEARCH, XX, XX, 1 January 1983 (1983-01-01), pages 173 - 186, XP002197412 *
S.R. FLANAGAN, D.C. HARROWVEN, M. BRADLEY: "Radical cyclisation reactions with indoles", TETRAHEDRON LETTERS, vol. 44, 2003, pages 1795 - 1798, XP002498176 *
VILLAMIL ET AL: "Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases", AMERICAN JOURNAL OF MEDICINE, XX, XX, vol. 118, no. 10, 27 September 2005 (2005-09-27), pages 1160 - 1163, XP005783681, ISSN: 0002-9343 *
WALKER G N ET AL: "Cyclization of acid lactams to spiro keto lactams. LIMITATIONS IN RING REARRANGEMENT OF FUSED .GAMMA.-LACTAMS IMPOSED BY A QUATERNARY CARBON ATOM. CYCLIZATION OF ACID LACTAMS TO SPIRO KETO LACTAMS", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON.; US, vol. 30, no. 9, 1 January 1965 (1965-01-01), pages 2973 - 2983, XP002399165, ISSN: 0022-3263 *
WU C C ET AL: "The effect of hypercholesterolemia on the sodium inward currents in cardiac myocyte", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY,, vol. 27, no. 6, 1 June 1995 (1995-06-01), pages 1263 - 1269, XP004997389, ISSN: 0022-2828 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105147760A (en) * 2015-09-28 2015-12-16 成都倍加特生物科技有限公司 Externally-used soak liquor capable of treating erythromelalgia and preparation method

Also Published As

Publication number Publication date
WO2008046087A2 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
WO2008046087A3 (en) Spiro compounds and their uses as therapeutic agents
MX2009003874A (en) Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents.
WO2008046084A3 (en) Spiroheterocyclic compounds and their uses as therapeutic agents
MY145694A (en) Spiroheterocyclic compounds and their uses as therapeutic agents
WO2006110917A3 (en) Spiro-oxindole compounds and their uses as therapeutic agents
MX2009008338A (en) Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions.
WO2008094909A3 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
WO2010045251A3 (en) Spiro-oxindole compounds and their use as therapeutic agents
WO2009155121A3 (en) Inhibitors of pi3 kinase
UA93872C2 (en) Dihydrothienopyrimidines for the treatment of inflammatory diseases
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
TW200728307A (en) Novel spirochromanone derivatives
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
WO2008008539A3 (en) Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
ATE517882T1 (en) QUINOLINE DERIVATIVES
WO2007020213A3 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
WO2011047173A3 (en) Pharmaceutical compositions for oral administration
WO2008151288A3 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
WO2008115999A8 (en) Biaryl and biheteroaryl compounds useful in treating iron disorders
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
MX2021011118A (en) Macrocyclic azolopyridine derivatives as eed and prc2 modulators.
WO2008109856A3 (en) Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions
WO2010132352A3 (en) Spiro compounds and their use as therapeutic agents
WO2006077024A3 (en) 5-aminoindole derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07854029

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07854029

Country of ref document: EP

Kind code of ref document: A2